Clinical trial will leverage the dotLab test to detect Troponin complexes.

Johns Hopkins University School of Medicine inked a deal to use Axela’s dotLab® technology in a clinical trial evaluating circulating cardiac Troponin complexes (cTn) in patient samples.

The study is trying to assess the prognostic value of Troponin complexes as well as post-translational modifications to cardiac Troponin I (cTnI) in patients with acute myocardial infarction (AMI).

Troponin is a complex of three proteins (cTnI, cTnC, and cTnT) that is integral to the contraction of cardiac muscle. It is released into the blood upon cardiac muscle necrosis and cell death.
The dotLab assay can detect circulating cTnI bound to cTnC and cTnT in the serum of patients with AMI. It is also able to probe the integrity of cTnI and determine if the protein is degraded by looking for the presence of specific epitopes.

Previous articleTGen to Assess febit’s DNA Capture Method in Next-Generation Sequencing Efforts
Next articleScientists Link Complementary Antibodies against Plasminogen to Increased Risk of Blood Clots in Vasculitis